Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | CES1 | P23141 | 1/20 | 0.44 |
| ▸ | MMP2 | P08253 | 4/20 | 0.42 |
| ▸ | CA12 | O43570 | 3/20 | 0.42 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | CA9 | Q16790 | 3/20 | 0.42 |
| ▸ | MMP1 | P03956 | 2/20 | 0.42 |
| ▸ | MMP3 | P08254 | 2/20 | 0.42 |
| ▸ | MMP8 | P22894 | 2/20 | 0.42 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11560406 | 1.00 | CES2 (0.44) | CES2CES1MMP2CA12CA1 | |
| SCHEMBL9089559 | 0.98 | MEN1 (0.40) | CES2CES1MMP2CA12CA1 | |
| SCHEMBL1132129 | 0.88 | LMNA (0.43) | MMP2CA12CA1CA2CA9 | |
| SCHEMBL18810568 | 0.80 | CES2 (0.42) | CES2CES1MMP2CA12CA1 | |
| SCHEMBL14892056 | 0.78 | MEN1 (0.36) | MMP1MMP3MMP8TSHRMEN1 | |
| SCHEMBL14892410 | 0.78 | MEN1 (0.36) | TSHRMEN1LMNAHPGDBLM | |
| SCHEMBL15511187 | 0.77 | MEN1 (0.34) | TSHRMEN1LMNAHPGDBLM | |
| SCHEMBL11542901 | 0.75 | LMNA (0.33) | MMP2CA12CA1CA2CA9 | |
| SCHEMBL11542904 | 0.75 | LMNA (0.33) | MMP2CA12CA1CA2CA9 | |
| SCHEMBL17558775 | 0.75 | LMNA (0.33) | TSHRMEN1LMNAHPGDBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190225618-A1 | IDO Inhibitors | MAUTINO MARIO (US) | 2019-07-25 | — | — | US | disclosed |
| EP-3189054-B1 | (1-FLUORO-CYCLOHEX-1-YL)-ETHYL SUBSTITUTED DIAZA- AND TRIAZA-TRICYCLIC COMPOUNDS AS INDOLE-AMINE-2,3-DIOXYGENASE (IDO) ANTAGONISTS FOR THE TREATMENT OF CANCER | MERCK PATENT GMBH (DE) | 2019-07-24 | — | — | EP | disclosed |
| US-10329297-B2 | Compounds for the inhibition of indoleamine-2,3-dioxygenase | MERCK PATENT GMBH (DE) | 2019-06-25 | — | — | US | disclosed |
| US-10233190-B2 | IDO inhibitors | NEWLINK GENETICS CORPORATION (US) | 2019-03-19 | — | — | US | disclosed |
| US-20190031665-A1 | DERIVATIVES OF PYRROLOIMIDAZOLE OR ANALOGUES THEREOF WHICH ARE USEFUL FOR THE TREATMENT OF INTER ALIA CANCER | EMCURE PHARMACEUTICALS LIMITED (IN) | 2019-01-31 | — | — | US | disclosed |
| CN-109071548-A | It can be used for treating the pyrroles's benzimidazole derivative or its analog of especially cancer | 埃姆库瑞医药品有限公司 | 2018-12-21 | — | — | CN | disclosed |
| EP-3400226-A1 | DERIVATIVES OF PYRROLOIMIDAZOLE OR ANALOGUES THEREOF WHICH ARE USEFUL FOR THE TREATMENT OF INTER ALIA CANCER | Emcure Pharmaceuticals Limited (IN) | 2018-11-14 | — | — | EP | disclosed |
| EP-3348558-A1 | COMPOSITIONS COMPRISING FUSED IMIDAZOLE DERIVATIVES USEFUL AS IDO INHIBITORS | Newlink Genetics Corporation (US) | 2018-07-18 | — | — | EP | disclosed |
| US-20180118753-A1 | IDO Inhibitors | NEWLINK GENETICS CORPORATION | 2018-05-03 | — | — | US | disclosed |
| US-9850248-B2 | IDO inhibitors | NEWLINK GENETICS CORPORATION (US) | 2017-12-26 | — | — | US | disclosed |
| EP-0667160-A2 | Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension | ALCON LABORATORIES, INC. (US) | 1995-08-16 | — | — | EP | disclosed |
| US-5405870-A | Platelet-aggregation inhibitors; useful in treatment of thrombosis | SANKYO COMPANY, LIMITED (JP) | 1995-04-11 | — | — | US | disclosed |
| EP-0389162-B1 | 2,5,6,7-Tetranor-4,8-inter-m-phenylene PGI2 derivatives | TORAY INDUSTRIES (JP) | 1993-12-08 | — | — | EP | disclosed |
| EP-0389162-A1 | 2,5,6,7-Tetranor-4,8-inter-m-phenylene PGI2 derivatives | TORAY INDUSTRIES, INC. (JP) | 1990-09-26 | — | — | EP | disclosed |
| US-4959391-A | LIPOXYGENASE INHIBITORS, LEUKOTRIENE DISEASES | GRUENENTHAL GMBH (DE) | 1990-09-25 | — | — | US | disclosed |
| US-4775692-A | ANTILIPEMIC, ANTICOAGULANT, HYPOTENSIVE, ANTISECRETORY AND ANTIULCER AGENT | TORAY INDUSTRIES, INC. (JP) | 1988-10-04 | — | — | US | disclosed |
| EP-0136779-B1 | NEW CARBACYCLIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | SANKYO COMPANY LIMITED (JP) | 1988-09-14 | — | — | EP | disclosed |
| US-4760087-A | 5-lipoxygenase inhibitor | GRUENENTHAL GMBH (DE) | 1988-07-26 | — | — | US | disclosed |
| US-4517202-A | HYPOTENSIVES AND ANTICOAGULANTS | MAY & BAKER LIMITED (GB) | 1985-05-14 | — | — | US | disclosed |
| EP-0136779-A1 | New carbacyclin derivatives, processes for their preparation and compositions containing them | SANKYO COMPANY LIMITED (JP) | 1985-04-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118753-A1 | IDO Inhibitors | IDO1, IDO2, INMT | CES2 3022/4885CES1 986/4885MMP2 895/4885 |
| US-20190225618-A1 | IDO Inhibitors | IDO1, IDO2, INMT | CES2 3047/4885CES1 958/4885MMP2 878/4885 |
| US-10329297-B2 | Compounds for the inhibition of indoleamine-2,3-dioxygenase | IDO1, IDO2, INMT | CES2 2645/4885CES1 1617/4885MMP2 1951/4885 |
| US-10233190-B2 | IDO inhibitors | IDO1, IDO2, INMT | CES2 3022/4885CES1 986/4885MMP2 895/4885 |
| US-20190031665-A1 | DERIVATIVES OF PYRROLOIMIDAZOLE OR ANALOGUES THEREOF WHICH ARE USEFUL FOR THE TREATMENT OF INTER ALIA CANCER | IDO1, IDO2, TDO2 | CES2 3338/4885CES1 1723/4885MMP2 2032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.